| Identification | More | [Name]
Phosphomycin calcium salt | [CAS]
26016-98-8 | [Synonyms]
FOSFOMYCIN
PHOSPHOMYCIN
PHOSPHOMYCIN CALCIUM SALT MONOHYDRATE
(1,2-epoxypropyl)-,calciumsalt(1:1),(1r,2s)-(-)-phosphonicaci
(3-methyloxiranyl)-,calciumsalt(1:1),(2r-cis)-phosphonicaci
calciumfosfomycin
calciumphosphomycin
calciumphosphonomycin
fosmicin
phosphomycincalcium
calcium hydrogen (2R-cis)-(3-methyloxiranyl)phosphonate
Fosfomycin caclium(+/-)
Phosphonic acid, (2R,3S)-3-methyloxiranyl-, calcium salt (1:1)
Fosfomycin calcium salt (1:1)
Phosphonic acid, (1,2-epoxypropyl)-, calcium salt (1:1), (1R,2S)-(-)-(8CI)
Phosphonic acid, (3-methyloxiranyl)-, calcium salt (1:1), (2R-cis)-
(-)-(1R,2S)-(1,2-Epoxypropyl)phosphonic acid
Fosfomycin calcium salt
Phosphomycin calcium salt
(-)-(1R,2S)-(1,2-Epoxypropyl)phosphonic acid, Fosfomycin calcium salt, Phosphonomycin | [EINECS(EC#)]
247-408-7 | [Molecular Formula]
C3H7O4P | [MDL Number]
MFCD00242804 | [Molecular Weight]
138.06 | [MOL File]
26016-98-8.mol |
| Chemical Properties | Back Directory | [storage temp. ]
2-8°C
| [solubility ]
1 M HCl: soluble50mg/mL | [form ]
neat | [color ]
White to off-white | [InChI]
InChI=1/C3H7O4P.Ca.2H/c1-2-3(7-2)8(4,5)6;;;/h2-3H,1H3,(H2,4,5,6);;;/t2-,3+;;;/s3 | [InChIKey]
YMZJBJPWTXJQMR-MUWMCQJSSA-L | [SMILES]
P([C@H]1O[C@H]1C)(O)(O)=O.[Ca] |&1:1,3,r| | [CAS DataBase Reference]
26016-98-8(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Uses]
Fosfomycin Calcium is a bacterial wall synthesis inhibitor. | [Definition]
ChEBI:Fosfomycin calcium is an organic molecular entity. | [in vivo]
Fosfomycin calcium (80 mg/kg; i.v.-i.v. or i.v.-p.o.) displays the protective effect on the nephrotoxicity of double beckacin, and is not affected by different administration routes[3].
Pharmacokinetic of Fosfomycin calcium in Rats[4]
| Dibekacin Dose (mg) | Vdss (l/kg) | β (min-1) | T1/2 (min) | Urinary recovery (%) | | 30 | 0.261 | 0.0244 | 28.4 | 85 |
| Animal Model: | Fischer 344 rats[3] | | Dosage: | 320 mg/kg | | Administration: | Intramuscular injection, 5 schedules: 1 h, 0.5 h earlier than dibekacin, concomitantly, 0.5 h later and 1 h later; 11 days | | Result: | Reduced polyuria, proteinuria, enzymes and cytosine caused by dibecacin (40 mg/kg), followed by the previous treatment.
|
| Animal Model: | Dehydrated Wistar rat with acute renal failure (8-week-old)[4] | | Dosage: | 120 mg/kg | | Administration: | Intravenous injection; once | | Result: | Recovered the exclusion rate of rats basically to normal, and improved the nephrotoxicity parameters.
Protects proximal tubular lysosomes from aminoglycosides by inhibiting myeloid formation and protecting the integrity of lysosomal membrane of rats treated with double bekacin.
|
| [storage]
Store at 2-8°C |
|
|